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    For decades, chronic kidney disease (CKD) has 
shown increased its incidence, severity and prevalence 
[1]. From the tremendous health and financial burden, 
mitigation for CKD exacerbation would be crucial. 
Among them, hyperuricemia has been clinically 
important problems and its prevalence has increased. 
From UK National Health Service (NHS) Digital 
Hospital Episode Statistics, unplanned admission to 
hospital due to rheumatoid arthritis (RA) or gout was 
studied during 2006-2017 [2].  The result showed  that  
RA incidence decreased from 8.6 to 4.3 per 100,000 
population/year, while gout incidence increased from 
7.9 to 12.5. Furthermore, provided prescriptions of 
allopurinol and colchicine have increased by 165.6% 
and 71.4%, respectively during this period. As regards 
to febuxostat, the prescription number has increased 
20-fold for 7 years, when the data of prescription was 
possible. Thus, these situations suggest the necessity of 
aggressive target-driven treatment for controlling 
hyperuricemia  and  gout  [2].   For  this  article,  latest  
 
Abstract 
    Hyperuricemia is a clinical important problem and its prevalence has been increased. Latest topics are 
described. The guideline adequately managing gout was published from American College of Rheumatology 
(ACR). Various optimal uses of urate-lowering therapy (ULT) were presented. The cardiorenal effects of 
hyperuricemia have been investigated for years. Regarding the patients on chronic kidney disease (CKD) and 
high risk of progression, ULT with allopurinol did not show the decline in eGFR compared to the control. 
Recently, dotinurad that is a new selective urate reabsorption inhibitor (SURI) would be applied to medical 
practice. Low-dose dotinurad showed satisfactory pharmacological efficacy. 
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topics are described for i) the latest guidelines, ii) the 
cardiorenal effects of gout and hyperuricemia and iii) 
uric acid-lowering drugs. 
 
    Firstly, the guideline for the management of 
controlling gout was published from ACR, which is 
known as American College of Rheumatology (ACR) 
[3]. The purpose was to give the adequate 
managements, such as optimal use for urate-lowering 
therapy (ULT), treatment for gout flares and 
recommendations for lifestyle and other medication. 
They used well-known GRADE methodology, meaning 
the Grading of Recommendations Assessment, 
Development and Evaluation. The results included 42 
recommendations. Among them, some important 
items from strong recommendations are i) ULT is 
needed for all cases such as recurrent gout flares, 
radiographic damage due to gout, or tophaceous gout, 
ii) For ULT initiation, allopurinol is the preferred first-
line including CKD stage >3, iii) starting low dose of 
allopurinol (≤100 mg/day, and lower in CKD) or 
febuxostat (<40 mg/day), iv) treat-to-target strategy 
with ULT would be uric acid value as < 6mg/dL [3]. 
 
    Secondly, in order to estimate the efficacy of ULT, 
systematic review was performed [4]. The biomarkers 
included BP, GFR, renal failure events, mortality from 
all causes and MACE (major adverse cardiovascular 
events). The analyses included 6458 cases in 28 trials, 
associated with 506 MACE and 266 renal failure 
events. Overall benefits for risk ratio were 0.93 in 
MACE, 1.04 for mortality of all causes and 0.97 in renal 
failure without significant difference. In contrast, ULT 
attenuated the decreasing slope of GRF for 
1.18mL/min/1.73 m2 a year, systolic BP for -3.45 mm 
Hg. Significant difference did not exist for reverse 
event risks between therapy group and control     
group [4]. 
 
    There was RCT for patients with CKD of stage 3-4, 
in which the influence of allopurinol for renal function 
has been evaluated [5]. Cases included 369 CKD 
patients, and they were divided into two groups for 
allopurinol vs control. The result showed that change 
in eGFR was not significantly different, which was -
3.33 vs -3.23 ml/min/1.73m2/year, respectively. 
Consequently,  for  patients  associated  with  high-risk 
 
 
progression and/or CKD, ULT by providing allopurinol 
has not brought the reduction of eGFR in comparison 
with the control.  
 
    Hyperuricemia is observed in DKD, which has been 
recognized as diabetic kidney disease. As to 
multicenter trial study, Preventing Early Renal Loss in 
Diabetes (PERL) was conducted [6]. It included 530 
Type 1 Diabetes mellitus (T1DM) cases and evaluated 
whether ULT on allopurinol would slow GFR loss in 
cases with DKD and T1DM. PERL determined clinical 
efficacy on allopurinol for mild-moderate DKD in Type 
1 diabetes mellitus (T1DM). Hyperuricemia may 
increase the exacerbation risk for DKD. PERL study 
group evaluated renal function by ULT with 
allopurinol in T1DM [7]. Totally 530 cases were 
classified into allopurinol and control groups. Uric acid 
value decreased from 6.1 mg/dL to 3.9 mg/dL for the 
former, and stable at 6.1 mg/dL for the latter. The 
reduction of eGFR a year was -3.0 vs -2.5 
mL/min/1.73m2/year without significant difference. 
Consequently, meaningful benefits of ULT with 
allopurinol was not observed for T1DM and early-to-
moderate DKD.  
 
    Some relationship may be present among MACE, all-
cause mortality (mort), user or non-user (+/-) of 
xanthine oxidase inhibitors (XOIs) with allopurinol 
(Allo) and febuxostat (Febu). There was a retrospective 
cohort study analyzing the association of MACE and 
XOIS, and between mort and XOIS [8]. Participants 
was 13997, and ratio of XOI user (+/-) was 
25.8%/74.2%. Both groups showed similar incidence 
of MACE/mort as hazard ratio (HR) 0.997/0.972. Feb 
user (n=276) showed similar MACE risk as Allo user 
(n=828), but decreased risk for heart failure-related 
hospitalizations (p=0.061). 
 
    As described above, ULT did not improve the 
cardiorenal outcome from some reports. Although it 
revealed the retrospective study, no increase in 
cardiovascular reverse events due to febuxostat have 
been found.  
 
    Thirdly, some tips for oral agents are described. 
Regarding febuxostat, pharmacokinetics for Asian race 
and body weight were investigated for 141 cases [9]. 
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The result revealed that Asian people showed 1.64-fold 
higher of under the curve (AUC) of febuxostat than 
Caucasians, which was not related to weight or other 
covariates. These findings would be beneficial when 
deciding the beginning the doses for febuxostat in 
Asian people. 
 
    The risk for hypersensitivity reactions (HSRs) was 
evaluated with febuxostat, colchicine and also 
allopurinol for a population-based investigation [10]. 
The data were obtained from 5% of Medicare 
beneficiary sample for related patients of a newly given 
prescription for three agents. Regarding the obtained 
results, crude HSRs data showed febuxostat 30.7, 
allopurinol 23.7 and colchicine 25.6 statistically for 
1000 person-years. When the standard prescription is 
to start allopurinol less than 200 mg/day, HR was 1.27 
in allopurinol ≥300 mg/day. 1.21 in DM and 1.32 in 
female, respectively. HSRs occurred in outpatient 
setting for 69% [10]. 
 
    A new selective urate reabsorption inhibitor (SURI), 
Dotinurad, was applied to medical practice recently 
[11]. It shows potent inhibitory efficacy at lower doses 
against the uptake of urate by urate transporter 1 
(URAT1), which is situated at the apical membrane of 
renal proximal tubular cells. For pharmacological 
characteristic of Dotinurad, human distribution 
volume was 0.182 L/kg, and its oral clearance was 
0.013 L/h/kg, respectively. These obtained data 
seemed to be lower, while plasma values were 
maintained enough at the higher levels. Furthermore, 
the differences among species were scarcely found 
with 94% of protein binding levels in the blood. 
Consequently, low-dose Dotinurad showed satisfactory 
pharmacological efficacy for a SURI [11]. Comparative 
clinical trials were conducted for dotinurad in 
hyperuricemia cases [12]. Subjects included 201 cases 
with hyperuricemia and/or without previous gout. 
Protocol included 102 of dotinurad and 99 of 
benzbromarone. Consequently, mean decreased 
percentage of UA level was 45.9% and 43.8%, 
respectively. In both groups, UA values decreased 
approximately from 9 mg/dl to 5 mg/dL. Non-
inferiority for dotinurad 2mg were shown to 




    In summary, current tips for hyperuricemia and 
ULT will be described. It will be hopefully useful for 
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